• 1
    Mosekilde L, Søgaard CH, Danielsen CC, Tørring O 1991 The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: A comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 129: 421428.
  • 2
    Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, Recker RR 1993 The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 132: 15771584.
  • 3
    Stewart AF, Cain RL, Burr DB, Jacob D, Turner CH, Hock JM 2000 Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: A comparison of human parathyroid hormone 1-34, parathyroid hormone-related protein 1-36, and SDZ-parathyroid hormone 893. J Bone Miner Res 15: 15171525.
  • 4
    Morley P, Whitfield JF, Willick GE, Ross V, MacLean S, Barbier JR, Isaacs RJ, Andreassen TT 2001 The effect of monocyclic and bicyclic analogs of human parathyroid hormone (hPTH)-(1-31)NH2 on bone formation and mechanical strength in ovariectomized rats. Calcif Tissue Int 68: 95101.
  • 5
    Jerome CP, Johnson CS, Vafai HT, Kaplan KC, Bailey J, Capwell B, Fraser F, Hansen L, Ramsay H, Shadoan M, Lees CJ, Thomsen JS, Mosekilde L 1999 Effect of treatment for 6 months with human parathyroid hormone (1-34) peptide in ovariectomized cynomolgus monkeys (Macaca fasicularis). Bone 25: 301309.
  • 6
    Hodsman AB, Hanley DA, Ettinger MP, Bolognese MA, Fox J, Metcalfe AJ, Lindsay R 2003 Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 52125220.
  • 7
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 14341441.
  • 8
    Greenspan SL, Bone HG, Marriott TB, Zanchetta JR, Ettinger MP, Hanley DA, Drezner MK, Miller PD 2005 Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH(1-84): Results from the TOP Study. J Bone Miner Res 20:S1; S56.
  • 9
    Horwitz MJ, Tedesco MB, Gundberg C, Garcia-Ocana A, Stewart AF 2003 Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88: 569575.
  • 10
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102: 16271633.
  • 11
    Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R 2001 Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: A paired biopsy study. J Bone Miner Res 16: 18461853.
  • 12
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF 2003 Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 18: 19321941.
  • 13
    Fox J, Miller MA, Recker RR, Bare SP, Smith SY, Moreau IA 2005 Treatment of postmenopausal osteoporotic women with parathyroid hormone 1-84 for 18 months increases cancellous bone formation and improves cancellous architecture: A study of iliac crest biopsies using histomorphometry and micro computed tomography. J Musculoskelet Neuron Interact 5: 356357.
  • 14
    Boutroy S, Bouxsein ML, Munoz F, Delmas PD 2005 In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral computed tomography. J Clin Endocrinol Metab 90: 65086515.
  • 15
    Turner CH 2002 Biomechanics of bone: Determinants of skeletal fragility and bone quality. Osteoporos Int 13: 97104.
  • 16
    Miller MA, Chin J, Miller SC, Fox J 1998 Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiency. Bone 23: 257266.
  • 17
    Hirano T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM 1999 Anabolic effects of human biosynthetic parathyroid hormone fragment (1-34), LY333334, on remodeling and mechanical properties of cortical bone in rabbits. J Bone Miner Res 14: 536545.
  • 18
    Boyce RW, Paddock CL, Franks AF, Jankowsky ML, Eriksen EF 1996 Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)2D3 or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J Bone Miner Res 11: 600613.
  • 19
    Jerome CP, Turner CH, Lees CJ 1997 Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis). Calcif Tissue Int 60: 265270.
  • 20
    Brommage R, Hotchkiss C, Lees CJ, Stancill MW, Hock JM, Jerome CP 1999 Daily treatment with human recombinant parathyroid hormone-(1-34), LY333334, for 1 year increases bone mass in ovariectomized monkeys. J Clin Endocrinol Metab 84: 37573763.
  • 21
    Sato M, Westmore M, Clendenon J, Smith S, Hannum B, Zeng GQ, Brommage R, Turner CH 2000 Three-dimensional modeling of the effects of parathyroid hormone on bone distribution in lumbar vertebrae of ovariectomized cynomolgus monkeys. Osteoporos Int 11: 871880.
  • 22
    Jerome CP, Burr DB, Van Bibber T, Hock JM, Brommage R 2001 Treatment with human parathyroid hormone (1-34) for 18 months increases cancellous bone volume and improves trabecular architecture in ovariectomized cynomolgus monkeys (Macaca fasicularis). Bone 28: 150159.
  • 23
    Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16: 157165.
  • 24
    Turner CH, Burr DB, Hock JM, Brommage R, Sato M 2001 The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys. Adv Exp Med Biol 496: 165179.
  • 25
    Sato M, Westmore M, Ma YL, Schmidt A, Zeng QQ, Glass EV, Vahle J, Brommage R, Jerome CP, Turner CH 2004 Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19: 623629.
  • 26
    Smith SY, Recker R, Kimmel DB, Akhter M, Metcalfe A, Dietrich J 1998 Efficacy of recombinant human parathyroid hormone (1-84) (rhPTH, (1-84)) in ovariectomized rhesus monkeys. Bone 23(Suppl): S633.
  • 27
    FDA Guidance 1994 Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Available at: Accessed November 30, 2005.
  • 28
    Binkley N, Kimmel D, Bruner J, Haffa A, Davidowitz B, Meng C, Schaffer V, Green J 1998 Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res 13: 17751782.
  • 29
    Vieth R, Kessler MJ, Pritzker KPH 1987 Serum concentrations of vitamin D metabolites in Cayo Santiago rhesus macaques. J Med Primatol 16: 349357.
  • 30
    Vieth R, Kessler MJ, Pritzker KPH 1990 Species differences in the binding kinetics of 25-hydroxyvitamin D3 to vitamin D binding protein. Can J Physiol Pharmacol 68: 13681371.
  • 31
    Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie L-G, Gallagher JC, Pavo I, Wang J, Eriksen EF 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90: 39703977.
  • 32
    Peel NF, Eastell R 1995 Comparison of rates of bone loss from the spine measured using two manufacturers' densitometers. J Bone Miner Res 10: 17961801.
  • 33
    Moreau I, Smith SY, Guldberg RE, Turner CH, Newman MK, Fox J 2005 Treatment of osteopenic rhesus monkeys with parathyroid hormone 1-84 for 16 months improves vertebral trabecular bone quantity and quality. J Bone Miner Res 20:S1; S412.
  • 34
    Divieti P, Inomata N, Chapin K, Singh R, Jüppner H, Bringhurst FR 2001 Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 142: 916925.